As important as it is to understand the features inherent to biologics that can trigger an immune response and work on designing less immunogenic molecules, it is equally critical to be able to design assays that can measure these differences and assure you of the improved success potential of a new design. Dr. Pratt will share her insight into the exciting new realm of sensitive surface plasmon resonance assays that allow for the necessary observation in changes in anti-drug antibody subtype distributions that would allow biologics designers to clearly visualize the results of their tests. Today we feature the session Next-Generation Assays for Immunogenicity Prediction. For more information on this event, taking place April 17-19, 2012, in Baltimore, MD, download the brochure.
Featured Session:Next-Generation Assays for Immunogenicity Prediction
Featured Speaker: Kathleen Pratt, PhD, Assistant Member, PUGET SOUND BLOOD CENTER RESEARCH INSTITUTE
About the session: Development of neutralizing anti-factor VIII (FVIII) antibodies is a serious complication of hemophilia A treatment through factor VIII (FVIII) infusions. We are studying mechanisms of T-cell and B-cell responses to FVIII. A central goal is to design FVIII proteins that are less likely to provoke immune responses in populations with higher-risk HLA haplotypes. A second goal is to design FVIII proteins that can evade inhibitory antibodies in patients who have already developed an anti-FVIII immune response. A sensitive surface plasmon resonance assay has been developed to follow changes in anti-drug antibody subtype distributions by direct analysis of serial plasma samples.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment